Is SCYNEXIS INC (SCYX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 48.5% / 30% | 176.6% / 30% | 30.6% / 30% | 114.55% / 5% | ✗ NOT HALAL |
| DJIM | 48.5% / 33% | 176.6% / 33% | 30.6% / 33% | 114.55% / 5% | ✗ NOT HALAL |
| MSCI | 17.9% / 33% | 65.4% / 33% | 11.3% / 33% | 114.55% / 5% | ✗ NOT HALAL |
| S&P | 48.5% / 33% | 176.6% / 33% | 30.6% / 33% | 114.55% / 5% | ✗ NOT HALAL |
| FTSE | 17.9% / 33% | 65.4% / 33% | 11.3% / 50% | 114.55% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | 56.4% | |
| Net Margin | -41.8% | |
| Return on Equity (ROE) | -16.5% | |
| Return on Assets (ROA) | -13.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$5M |
| Free Cash Flow | -$5M |
| Total Debt | $2M |
| Debt-to-Equity | 4.4 |
| Current Ratio | 7.0 |
| Total Assets | $59M |
Price & Trading
| Last Close | $0.84 |
| 50-Day MA | $0.79 |
| 200-Day MA | $0.77 |
| Avg Volume | 404K |
| Beta | 1.3 |
|
52-Week Range
$0.56
| |
About SCYNEXIS INC (SCYX)
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is SCYNEXIS INC (SCYX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), SCYNEXIS INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is SCYNEXIS INC's debt ratio?
SCYNEXIS INC's debt ratio is 48.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 17.9%.
What are SCYNEXIS INC's key financial metrics?
SCYNEXIS INC has a market capitalization of $36M, and revenue of $21M. The company maintains a gross margin of 100.0% and a net margin of -41.8%. Return on equity stands at -16.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.